[CCXI] ChemoCentryx, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 200.19 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 8.15 Change: 0.59 (7.8%)
Ext. hours: Change: 0 (0%)

chart CCXI

Refresh chart

Strongest Trends Summary For CCXI

CCXI is in the long-term up 236% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe Crohn?s disease; CCX140 that is in Phase II clinical trial for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company?s drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated renal vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammato

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding44.29 M EPS-0.65 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-11.23
P/E To EPS Growth P/S P/BV2.01 Price/Cash Per Share2.67
Price/Free Cash Flow-5.77 ROA-44.16% ROE-47.68% ROI
Current Ratio9.82 Quick Ratio Long Term Debt/Equity Debt Ratio0.08
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities330 K Cash From Investing Activities18.71 M Cash From Operating Activities-9.68 M Gross Profit
Net Profit-12.01 M Operating Profit-12.11 M Total Assets107.34 M Total Current Assets76.05 M
Total Current Liabilities7.75 M Total Debt Total Liabilities7.93 M Total Revenue
Technical Data
High 52 week14.85 Low 52 week9.15 Last close13.61 Last change3.73%
RSI41.87 Average true range0.61 Beta1.27 Volume333.1 K
Simple moving average 20 days1.66% Simple moving average 50 days13.42% Simple moving average 200 days18.56%
Performance Data
Performance Week9.94% Performance Month2.25% Performance Quart17.02% Performance Half26.02%
Performance Year25.21% Performance Year-to-date24.75% Volatility daily2.86% Volatility weekly6.4%
Volatility monthly13.11% Volatility yearly45.41% Relative Volume412.55% Average Volume506.25 K
New High New Low

News

2019-06-11 08:30:00 | ChemoCentryx to Present at Two Upcoming Investor Conferences

2019-06-06 07:37:34 | The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering

2019-05-20 09:00:01 | ChemoCentryx CCXI Moves to Buy: Rationale Behind the Upgrade

2019-05-09 11:07:07 | Hedge Funds Have Never Been More Bullish On ChemoCentryx Inc CCXI

2019-05-07 11:18:19 | Edited Transcript of CCXI earnings conference call or presentation 6-May-19 9:00pm GMT

2019-05-07 01:29:50 | ChemoCentryx Inc CCXI Q1 2019 Earnings Call Transcript

2019-05-06 18:15:10 | ChemoCentryx CCXI Reports Q1 Loss, Misses Revenue Estimates

2019-05-06 17:12:17 | ChemoCentryx: 1Q Earnings Snapshot

2019-05-06 16:05:00 | ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights

2019-04-29 08:30:00 | ChemoCentryx to Hold First Quarter 2019 Financial Results Conference Call on Monday, May 6, 2019

2019-04-02 08:30:00 | ChemoCentryx to Present at the H.C. Wainwright Global Life Sciences Conference

2019-03-28 08:30:00 | ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors

2019-03-19 08:41:12 | ChemoCentryx CCXI Looks Good: Stock Adds 5.5% in Session

2019-03-12 19:36:18 | Edited Transcript of CCXI earnings conference call or presentation 11-Mar-19 9:00pm GMT

2019-03-12 01:28:36 | ChemoCentryx CCXI Q4 2018 Earnings Conference Call Transcript

2019-03-11 17:30:09 | ChemoCentryx CCXI Reports Q4 Loss, Lags Revenue Estimates

2019-03-11 16:26:11 | ChemoCentryx: 4Q Earnings Snapshot

2019-03-11 16:05:00 | ChemoCentryx Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights

2019-03-04 08:30:00 | ChemoCentryx to Hold Fourth Quarter 2018 Financial Results Conference Call on Monday, March 11, 2019

2019-02-26 08:20:00 | New Research: Key Drivers of Growth for Ellie Mae, Spotify Technology SA, Bristow Group, Teradata, ChemoCentryx, and AgroFresh Solutions — Factors of Influence, Major Initiatives and Sustained Production

2019-02-20 08:30:00 | ChemoCentryx to Present at the 8th Annual SVB Leerink Global Healthcare Conference

2019-01-24 08:30:00 | ChemoCentryx Announces Withdrawal of Phase II-Based Conditional Marketing Authorization CMA Application for ANCA-Associated Vasculitis in Europe; Phase III ADVOCATE Trial Data Release Planned for Q4 2019

2019-01-02 08:30:00 | ChemoCentryx to Present at the 37th Annual J.P. Morgan Healthcare Conference

2018-11-29 16:05:00 | ChemoCentryx’s Novel Small Molecule Antagonists of Checkpoint Inhibitors and Chemokine Receptors to be Presented at the American Association for Cancer Research AACR Tumor Immunology and Immunotherapy Conference

2018-11-27 08:50:00 | New Research Coverage Highlights Ralph Lauren, CECO Environmental, PRA Group, ChemoCentryx, SunCoke Energy Partners, and Delek US — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-11-20 08:30:00 | ChemoCentryx to Present at the 30th Annual Piper Jaffray Healthcare Conference

2018-11-09 01:37:13 | Edited Transcript of CCXI earnings conference call or presentation 8-Nov-18 10:00pm GMT

2018-11-08 19:00:12 | ChemoCentryx CCXI Reports Q3 Loss, Lags Revenue Estimates

2018-11-08 17:58:31 | ChemoCentryx: 3Q Earnings Snapshot

2018-11-08 16:05:00 | ChemoCentryx Reports Third Quarter 2018 Financial Results and Recent Highlights

2018-11-01 08:30:00 | ChemoCentryx to Hold Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018

2018-10-30 10:33:02 | Earnings Preview: ChemoCentryx CCXI Q3 Earnings Expected to Decline

2018-10-25 13:30:00 | Presentations at ASN Kidney Week 2018 Highlight ChemoCentryx Platform in Treatment of ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis FSGS

2018-10-16 09:20:00 | Analysis: Positioning to Benefit within ChemoCentryx, Armstrong Flooring, Kornit Digital, NewLink Genetics, Silvercorp Metals, and Halcon Resources — Research Highlights Growth, Revenue, and Consolidated Results

2018-09-27 22:20:00 | ChemoCentryx Determines Not to Proceed with Public Offering of Common Stock

2018-09-26 18:28:00 | After-hours buzz: BBBY, KRP & more

2018-09-26 16:01:00 | ChemoCentryx Announces Proposed Public Offering of Common Stock

2018-09-26 08:30:00 | ChemoCentryx to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

2018-09-18 01:03:01 | VIFOR PHARMA GROUP INCREASES EQUITY INVESTMENT IN CHEMOCENTRYX

2018-08-28 08:30:00 | ChemoCentryx to Present at Two Upcoming Investor Conferences

2018-08-25 19:45:59 | Edited Transcript of CCXI earnings conference call or presentation 9-Aug-18 9:00pm GMT

2018-08-20 08:20:00 | Recent Analysis Shows Ferroglobe, AXT, ChemoCentryx, RedHill Biopharma, GTx, and Achillion Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth

2018-08-09 19:00:11 | ChemoCentryx CCXI Reports Q2 Loss, Misses Revenue Estimates

2018-08-09 17:55:28 | ChemoCentryx: 2Q Earnings Snapshot

2018-08-09 16:05:00 | ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights

2018-08-02 08:30:00 | ChemoCentryx to Hold Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018

2018-07-13 14:24:06 | J&J JNJ to Pay $4.69 Billion to Some Women in Talc Lawsuit

2018-07-12 09:21:01 | Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer

2018-07-10 10:37:02 | KemPharm Stock Down Despite Positive Data on ADHD Candidate

2018-07-02 10:34:02 | Jazz Sells Pain Drug Prialt's Rights to TerSera Therapeutics